Hillman Company’s Cartesian Therapeutics RNAC Stock Holding History

Hillman Company’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-564	Closed	-$290K	–	17
2016 Q4	$290K	Buy	+564	New	+$330K	0.1%	16

Other funds holding RNAC

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hillman Company's RNAC Position: Q1 2017 in Review

Hillman Company sold out of Cartesian Therapeutics (RNAC) in Q1 2017, closing a stake of 564 shares — an estimated $290K sold.

Hillman Company first reported a position in RNAC in Q4 2016 and held it in 1 quarter. The position peaked at $290K in Q4 2016. 46 funds tracked by Wall St. Rank hold RNAC as of Q1 2017.

Hillman Company reported no remaining Cartesian Therapeutics position as of Q1 2017 after selling out during the quarter.
Hillman Company sold 564 Cartesian Therapeutics shares in Q1 2017, an estimated $290K.
Hillman Company first reported a position in Cartesian Therapeutics in Q4 2016 and held it in 1 quarter.
Hillman Company's Cartesian Therapeutics position peaked at $290K in Q4 2016.
46 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2017.

Based on Hillman Company's 13F filing for Q1 2017, filed 17 Apr 2017.